Engineering and Development

Customer Service and Support

Management and Executive

Product Management

Sales

Marketing

Accounting and Finance

Chief Commercial Officer (CCO)

Veracyte initiated with neutral view at Canaccord, here's why

Freedom Capital Markets Initiates Coverage of Veracyte With Buy Rating and $45 Price Target

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Veracyte Insider Sold Shares Worth $753,204, According to a Recent SEC Filing

Revenue Cycle Reimbursement Specialist

Veracyte is a global diagnostics company focused on transforming cancer care for patients worldwide. They are seeking a Revenue Cycle Reimbursement Specialist to manage health plan prior authorization and provide analytics on the medical billing and reimbursement cycle.

Vice President, Employment Law & Global HR

Sr Director, Total Rewards

Senior Revenue Analyst

Sign up with Google

Sign in with Google